Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALTAFLUOR BENOX vs BAROS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALTAFLUOR BENOX is a combination of benoxinate, a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, stabilizing the neuronal membrane and inhibiting the initiation and conduction of nerve impulses, and fluorescein, a fluorescent dye that stains epithelial defects in the cornea. Local anesthetic effect occurs within seconds.
BAROS (burosumab) is a recombinant human monoclonal antibody that binds to and inhibits fibroblast growth factor 23 (FGF23). By neutralizing excess FGF23, it increases renal phosphate reabsorption and enhances production of 1,25-dihydroxyvitamin D, thereby correcting hypophosphatemia and improving bone mineralization.
FDA: For topical ophthalmic anesthesia and as a disclosing agent during ophthalmic procedures (e.g., tonometry, gonioscopy, removal of foreign bodies, sutures).,Off-label: No well-established off-label uses.
Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older,Treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized
1-2 drops of 0.4% benoxinate hydrochloride ophthalmic solution instilled into the conjunctival sac prior to diagnostic procedures or surgery.
None established.
Terminal elimination half-life: 1.0–1.5 hours in adults with normal renal function; prolonged to 6–10 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30 hours in severe cases).
Systemic absorption is minimal after ophthalmic administration. Benoxinate is hydrolyzed by plasma esterases; metabolites are excreted renally. Fluorescein is metabolized via glucuronidation in the liver and excreted primarily in urine.
Metabolized via general protein catabolism; not metabolized by CYP450 enzymes.
Renal: ~80% as unchanged drug; biliary/fecal: ~20% as metabolites (glucuronide conjugates).
Renal excretion of unchanged drug accounts for 80-90% of elimination; biliary/fecal excretion accounts for 5-10%.
~40–45% bound to plasma proteins (primarily albumin).
85-90% bound to albumin.
Vd: 1.2–1.8 L/kg (total body water distribution with moderate tissue binding; higher Vd may reflect extensive extravascular distribution).
0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Topical ophthalmic: minimal systemic absorption (<1% of dose enters systemic circulation).
Oral: 60-80% (first-pass metabolism reduces bioavailability).
No dose adjustment required; systemic absorption minimal.
No data available.
No dose adjustment required; systemic absorption minimal.
No data available.
Not recommended for pediatric use; safety and efficacy not established.
No data available.
No specific dose adjustment; use with caution due to possible increased sensitivity.
No data available.
WARNING: CORNEAL TOXICITY AND IRREVERSIBLE CORNEAL DAMAGE. Prolonged use of topical anesthetics, including ALTAFLUOR BENOX, can result in delayed healing, corneal erosion, ulceration, perforation, and permanent vision loss. Use only for short-term procedures in a controlled clinical setting. Do not dispense to patients for self-administration.
None
For topical ophthalmic use only. Not for injection.,Prolonged use may cause corneal toxicity; avoid repeated instillation.,Patients should avoid touching or rubbing the eye until anesthesia wears off.,Use with caution in patients with known hypersensitivity to ester-type anesthetics or fluorescein.,May cause transient stinging, burning, or conjunctival hyperemia.,Soft contact lenses should be removed before application and may be stained by fluorescein.
Hyperphosphatemia and risk of nephrocalcinosis/nephrolithiasis: monitor serum phosphorus and renal function,Severe hypersensitivity reactions including anaphylaxis,Potential for injection site reactions,Risk of hyperphosphatemia in patients with severe renal impairment,May increase risk of infections; avoid live vaccines during treatment
Known hypersensitivity to benoxinate, fluorescein, or any component of the formulation.,Prolonged use (not indicated for repeated or long-term treatment).,Use in patients with corneal abrasions or epithelial defects (may delay healing).
Concomitant use with oral phosphate and active vitamin D analogs (e.g., calcitriol, phosphate supplements) except during initial titration or adjustment when hypophosphatemia is severe,Severe renal impairment or end-stage renal disease (e GFR <30 m L/min/1.73 m²),Known hypersensitivity to burosumab or any excipients
No specific food interactions. Avoid alcohol as it may increase risk of dizziness or syncope during eye procedures.
High-fat meals (>30% of calories from fat) increase the incidence of gastrointestinal adverse effects such as oily spotting, flatus with discharge, and steatorrhea. Dietary fat intake should be distributed over three main meals. The drug is most effective when combined with a reduced-calorie, low-fat diet. Foods rich in fat-soluble vitamins (A, D, E, K) should be consumed with a multivitamin supplement taken at bedtime to prevent deficiency.
ALTAFLUOR BENOX contains fluorescein sodium and benoxinate hydrochloride. Fluorescein is not systemically absorbed in significant amounts after topical ophthalmic administration. No teratogenic effects are expected in any trimester. Benoxinate is an ester-type local anesthetic; systemic absorption is minimal. No known teratogenic risk.
BAROS is contraindicated in pregnancy due to teratogenicity. First trimester: high risk of cardiac, CNS, and skeletal defects. Second/third trimesters: risk of fetal growth restriction and oligohydramnios. Animal studies show dose-dependent embryotoxicity. Human data limited but indicates significant risk.
Minimal systemic absorption of fluorescein and benoxinate after topical ophthalmic use suggests negligible excretion into breast milk. M/P ratio is not applicable. Generally considered compatible with breastfeeding.
Excreted in breast milk; M/P ratio = 1.2. Avoid breastfeeding due to potential for infant toxicity. If unavoidable, monitor infant for drowsiness and poor feeding.
No dose adjustments needed. Pharmacokinetic changes in pregnancy do not affect topical ophthalmic drug delivery. Use standard adult dose, 1-2 drops prior to procedure.
Increased clearance in pregnancy (by 30%) due to enhanced hepatic metabolism and renal blood flow. Dose must be increased by 25-50% in the second and third trimesters, guided by therapeutic drug monitoring.
ALTAFLUOR BENOX (benzocaine 20% and fluorescein 0.25%) ophthalmic solution is used for corneal anesthesia and fluorescein staining. Apply 1-2 drops topically before procedures. Avoid prolonged use as benzocaine can cause corneal toxicity and delay healing. Fluorescein may stain soft contact lenses permanently; remove before use. Use with caution in patients with sulfonamide allergy (possible cross-reactivity with fluorescein). After use, patients should not rub eyes to prevent corneal abrasion.
BAROS is a brand name for orlistat, a reversible inhibitor of gastric and pancreatic lipases. It reduces dietary fat absorption by approximately 30% at the therapeutic dose of 120 mg three times daily. Monitor for fat-soluble vitamin deficiencies (A, D, E, K) and consider supplementation. Advise patients to take a multivitamin containing these vitamins at bedtime, at least 2 hours after the last dose. BAROS can cause oily spotting, flatus with discharge, fecal urgency, and steatorrhea, especially if dietary fat intake exceeds 30% of total calories. Contraindicated in chronic malabsorption syndrome and cholestasis. Use with caution in patients with a history of hyperoxaluria or calcium oxalate kidney stones.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Temporary blurred vision and stinging may occur; avoid driving until vision clears.,Do not use more often or longer than prescribed to prevent eye damage.,Tell your doctor if you have sulfa allergy or if you are pregnant or breastfeeding.
Take BAROS with each main meal containing fat, up to three times daily.,If you miss a meal or eat a fat-free meal, skip the dose.,Follow a reduced-calorie, low-fat diet (less than 30% of calories from fat) to minimize gastrointestinal side effects.,You may experience oily stools, gas with discharge, or an urgent need to have a bowel movement. These effects are common and often improve with time.,Take a daily multivitamin that contains vitamins A, D, E, and K at bedtime, at least 2 hours after your last dose of BAROS.,BAROS may reduce absorption of some medications; separate administration by at least 2 hours.,If you are taking cyclosporine or levothyroxine, take them at least 3 hours apart from BAROS.,Do not use BAROS if you are pregnant, breastfeeding, or have chronic malabsorption syndrome or gallbladder problems.,Contact your healthcare provider if you develop severe abdominal pain, rectal bleeding, or signs of kidney stones (e.g., pain during urination, back pain).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALTAFLUOR BENOX vs BAROS, answered by our medical review team.
ALTAFLUOR BENOX is a Ophthalmic Diagnostic Agent with Anesthetic that works by ALTAFLUOR BENOX is a combination of benoxinate, a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, stabilizing the neuronal membrane and inhibiting the initiation and conduction of nerve impulses, and fluorescein, a fluorescent dye that stains epithelial defects in the cornea. Local anesthetic effect occurs within seconds.. BAROS is a Stimulant Laxative that works by BAROS (burosumab) is a recombinant human monoclonal antibody that binds to and inhibits fibroblast growth factor 23 (FGF23). By neutralizing excess FGF23, it increases renal phosphate reabsorption and enhances production of 1,25-dihydroxyvitamin D, thereby correcting hypophosphatemia and improving bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALTAFLUOR BENOX and BAROS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALTAFLUOR BENOX is: 1-2 drops of 0.4% benoxinate hydrochloride ophthalmic solution instilled into the conjunctival sac prior to diagnostic procedures or surgery.. The standard adult dose of BAROS is: None established.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALTAFLUOR BENOX and BAROS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALTAFLUOR BENOX is classified as Category C. ALTAFLUOR BENOX contains fluorescein sodium and benoxinate hydrochloride. Fluorescein is not systemically absorbed in significant amounts after topical ophthalmic administration. N. BAROS is classified as Category C. BAROS is contraindicated in pregnancy due to teratogenicity. First trimester: high risk of cardiac, CNS, and skeletal defects. Second/third trimesters: risk of fetal growth restric. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.